MDT

95.31

-1.26%↓

VEEV

287.1

-0.28%↓

139.44

+0.99%↑

HQY

92.23

-1.52%↓

TLRY

1.67

+5.03%↑

MDT

95.31

-1.26%↓

VEEV

287.1

-0.28%↓

139.44

+0.99%↑

HQY

92.23

-1.52%↓

TLRY

1.67

+5.03%↑

MDT

95.31

-1.26%↓

VEEV

287.1

-0.28%↓

139.44

+0.99%↑

HQY

92.23

-1.52%↓

TLRY

1.67

+5.03%↑

MDT

95.31

-1.26%↓

VEEV

287.1

-0.28%↓

139.44

+0.99%↑

HQY

92.23

-1.52%↓

TLRY

1.67

+5.03%↑

MDT

95.31

-1.26%↓

VEEV

287.1

-0.28%↓

139.44

+0.99%↑

HQY

92.23

-1.52%↓

TLRY

1.67

+5.03%↑

Home・Listă Acțiuni・Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics Inc

Închisă

SectorSănătate

21.62 6.24

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

20.29

Maxim

21.69

Indicatori cheie
By Trading Economics
Venit	9.2M -16M
Vânzări	16M 82M
Marjă de profit	-19.491
Angajați	342
EBITDA	6.7M -12M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+9.99% upside

Dividende
By Dow Jones
Următoarele câștiguri	28 oct. 2025

Statistici piață
By TradingEconomics
Capitalizare de piață	754M 2.5B
Deschiderea anterioară	15.38
Închiderea anterioară	21.62

Scor tehnic

By Trading Central

Încredere

Strong Bearish Evidence

12.42 / 14.93 Suport & Rezistență

Arcutis Biotherapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

15 oct. 2025, 23:25 UTC

Principalele dinamici ale pieței

Salesforce Rises on New FY30 Financial Targets

15 oct. 2025, 18:52 UTC

Câștiguri

Principalele dinamici ale pieței

Prologis Shares Gain on Raised Outlook, Data Center Growth

15 oct. 2025, 18:30 UTC

Achiziții, Fuziuni, Preluări

Constellation Software to Buy U.K.'s Tecvia Holding

15 oct. 2025, 17:19 UTC

Achiziții, Fuziuni, Preluări

Drahi's Altice Rejects $20 Billion Joint Offer From Peers -- 2nd Update

15 oct. 2025, 17:11 UTC

Achiziții, Fuziuni, Preluări

Anglo American, MMG Offer Concessions to EU Merger Watchdog in Nickel Deal Probe

15 oct. 2025, 23:48 UTC

Market Talk

Gold Steady, Supported by Expectations of Ongoing Central Bank Purchases -- Market Talk

15 oct. 2025, 23:38 UTC

Market Talk

Nikkei May Rise, Tracking Gains Across Most U.S. Equity Markets -- Market Talk

15 oct. 2025, 22:37 UTC

Market Talk

Economic Stars Are Aligning for RBA -- Market Talk

15 oct. 2025, 21:44 UTC

Câștiguri

Stock Rally Is Lifting Wealth Managers. How Much Is Charles Schwab Benefiting? -- Barrons.com

15 oct. 2025, 20:50 UTC

Market Talk

Câștiguri

Financial Services Roundup: Market Talk

15 oct. 2025, 20:44 UTC

Achiziții, Fuziuni, Preluări

Restaurant Brands Recommends Hldrs Do Not Tender Their Shrs to the Offer >QSR.T

15 oct. 2025, 20:44 UTC

Achiziții, Fuziuni, Preluări

Restaurant Brands Notified of Unsolicited Mini-Tender Offer to Buy Shrs at $28.80/Shr

15 oct. 2025, 20:43 UTC

Achiziții, Fuziuni, Preluări

Restaurant Brands Notified of Unsolicited Mini-Tender Offer by NY Stk and Bond LLC to Purchase Up to 10,000 Common Shrs >QSR.T

15 oct. 2025, 20:34 UTC

Câștiguri

Prologis Raises Outlook as Warehouse Leasing Picks Up -- WSJ

15 oct. 2025, 20:31 UTC

Achiziții, Fuziuni, Preluări

RBI Recommends Hldrs Reject NYSB's "Mini-Tender Offer"

15 oct. 2025, 20:17 UTC

Achiziții, Fuziuni, Preluări

GE Vernova Stock Feill With Latest Call to Sell -- Barrons.com

15 oct. 2025, 19:06 UTC

Câștiguri

These Stocks Are Moving the Most Today: Bank of America, Morgan Stanley, ASML, AMD, Nvidia, Bunge, Progressive, Abbott, and More -- Barrons.com

15 oct. 2025, 19:04 UTC

Market Talk

Oil Futures Post Back-to-Back Losses -- Market Talk

15 oct. 2025, 18:46 UTC

Market Talk

U.S. Natural Gas Futures Slip Ahead of Storage Data -- Market Talk

15 oct. 2025, 18:23 UTC

Câștiguri

This Insurer Is the One of the Worst Stocks in the S&P 500 Today. Here's Why. -- Barrons.com

15 oct. 2025, 17:37 UTC

Achiziții, Fuziuni, Preluări

Constellation Software's Harris Operating Group Enters Into Agreement To Acquire TECVIA Holding GmbH >CSU.T

15 oct. 2025, 17:34 UTC

Market Talk

Oil Futures Lose Ground on Trade, Oversupply Concerns -- Market Talk

15 oct. 2025, 16:57 UTC

Câștiguri

The Nation's Biggest Banks Are Saying the Economy Is Still Strong -- WSJ

15 oct. 2025, 16:51 UTC

Achiziții, Fuziuni, Preluări

EssilorLuxottica Doesn't Disclose Financial Details

15 oct. 2025, 16:50 UTC

Achiziții, Fuziuni, Preluări

EssilorLuxottica: RetinAI Partners With Pharmaceutical Companies, Research Organizations

15 oct. 2025, 16:49 UTC

Achiziții, Fuziuni, Preluări

EssilorLuxottica: Deal Reinforces the Group's Med-Tech Journey

15 oct. 2025, 16:48 UTC

Achiziții, Fuziuni, Preluări

EssilorLuxottica: Ikerian Specializes in Artificial Intelligence, Data Management in Eyecare

15 oct. 2025, 16:48 UTC

Achiziții, Fuziuni, Preluări

EssilorLuxottica: Ikerian Is a Health Technology Company, Operating Under the RetinAI Brand

15 oct. 2025, 16:47 UTC

Achiziții, Fuziuni, Preluări

EssilorLuxottica Buys Ikerian

15 oct. 2025, 16:34 UTC

Market Talk

AMD Data Center Agreements Will Provide Big Revenue Growth -- Market Talk

Comparație

Modificare preț

Arcutis Biotherapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

9.99% sus

Prognoză pe 12 luni

Medie 22.79 USD 9.99%

Maxim 29 USD

Minim 14.29 USD

În baza a 8 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruArcutis Biotherapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

8 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 8 analiști care au acordat evaluări ale acțiunilor Arcutis Biotherapeutics Inc - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

12.42 / 14.93Suport & Rezistență

Recent bearish events outweigh bullish events.

There is one bullish event.

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.